Market Need Target psoriasis patients in the US and globally by partnering with dermatology clinics, patient advocacy groups, and insurers to expand access to illuvinate as a home-use solution that accelerates relief within six weeks.

Early Market Leverage Northern California launch as a proof of concept to drive regional key account engagement with dermatology practices, specialty clinics, and durable medical equipment suppliers for broadened distribution.

Clinical Advantage Highlight FDA-cleared status and home-use capability to differentiate from in-clinic therapies; position illuvinate as a convenient, patient-friendly option that can reduce clinic visit frequency and increase adherence.

Growth Funding With evidence of $2M funding and limited current revenue, target strategic investors and corporate partnerships that can scale manufacturing, regulatory support, and national distribution, aligning with a lean-to-scale growth plan.

Strategic Alliances Identify opportunities to collaborate with large pharma and medical device distributors for rapid commercialization, while exploring payer coverage and reimbursement strategies to improve patient access and sales velocity.